Skip to main content
. 2017 Nov 23;12:98. doi: 10.1186/s13019-017-0668-3

Fig. 1.

Fig. 1

Case 1. PET-CT showing the high fluorodeoyglucose (FDG) uptake of the primary lesion and swelling of the #2 (a) and #4 lymph nodes (b) before gefitinib therapy. PET-CT showing the regression of the primary lesion and the #2 (c) and #4 (d) lymph nodes after gefitinib therapy. Histological findings (hematoxylin-eosin staining) showing residual viable tumor cells in the primary lesion (e-f)